Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B
Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
No study has reported on the comparative effect of continuing lamivudine plus adefovir versus
switching to telbivudine plus adefovir in HBeAg-positive lamivudine-refractory chronic
hepatitis B patients who have suboptimal response to lamivudine plus adefovir. The goal of
this study is to compare the efficacy of continuing lamivudine plus adefovir versus switching
to telbivudine plus adefovir directly in patients with lamivudine-refractory chronic
hepatitis B patients who have suboptimal response to lamivudine plus adefovir for at least 12
months.